SLC25A20 (O43772) variants and mutations
SLC25A20 (also known as O43772) is a human protein-coding gene encoding a mitochondrial carnitine/acylcarnitine carrier protein. It exchanges acylcarnitines and free carnitine across the inner mitochondrial membrane, allowing long-chain fatty acids to enter the beta-oxidation pathway. Biallelic loss-of-function variants cause carnitine-acylcarnitine translocase deficiency, often with severe neonatal hypoglycemia, hyperammonemia, and cardiomyopathy. This analysis covers 529 SLC25A20 variants and mutations. Of these, 92% have computational variant effect predictions. Disease context includes carnitine-acylcarnitine translocase deficiency, hereditary disease, and Abnormality of the skeletal system. Example SLC25A20 variants include M1V, A2V, and D3N.
Variant analysis overview
- Gene: SLC25A20
- Protein: O43772
- UniProt accession: O43772
- Organism: Homo sapiens
- Variants analyzed: 529
- Variant scope: all variants
- Completed: 2026-08-20
Variant and mutation evidence
- Variant composition: 357 unspecified-consequence records; 86 missense variants; 57 synonymous variants; 16 frameshift variants; 4 splice-region variants; 5 stop-gained variants; 1 in-frame deletions; 3 substitution
- Prediction scores: 487 variants have prediction scores (92% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: carnitine-acylcarnitine translocase deficiency, hereditary disease, Abnormality of the skeletal system, Pancreatic pseudocyst, neoplasm, hepatocellular carcinoma, alcohol drinking, atrial fibrillation, urolithiasis, hyperinsulinemic hypoglycemia, familial, 4, uveitis, cancer.
Protein structure and variant hotspots
- Protein features: 6 transmembrane segments; 5 post-translational modification sites.
- Structural context: 205 variants have structural context.
- PTM context: 8 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable SLC25A20 variants
Examples include M1V, A2V, D3N, Q4*, Q4E, Q4K, Q4P, P5A. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1V (p.Met1Val), rs745490594, ClinGen CA2387535, ClinVar RCV003513474, MetaLR 0.60, MetaSVM 0.20, Pathogenic, Carnitine acylcarnitine translocase deficiency
- A2V (p.Ala2Val), TOPMed rs1304635439, gnomAD rs1304635439, REVEL 0.34, MetaLR 0.32
- D3N (p.Asp3Asn), rs562426357, 1000Genomes rs562426357, REVEL 0.08, MetaLR 0.27, Variant assessed as somatic; moderate impact.
- Q4* (p.Gln4Ter), rs756998699, ClinGen CA312985, ClinVar RCV000186165, ClinVar RCV000689326, CADD 25.90, Pathogenic
- Q4E (p.Gln4Glu), ExAC rs756998699, TOPMed rs756998699, gnomAD rs756998699, REVEL 0.19, MetaLR 0.24, Pathogenic
- Q4K (p.Gln4Lys), ExAC rs756998699, TOPMed rs756998699, gnomAD rs756998699, REVEL 0.16, MetaLR 0.24, Pathogenic
- Q4P (p.Gln4Pro), TOPMed rs1327873443
- P5A (p.Pro5Ala), rs2083929089, ClinGen CA352639599, ClinVar RCV002897271, TOPMed rs2083929089, AlphaMissense 0.06, MetaLR 0.21, Likely benign, Inborn genetic diseases
- P5S (p.Pro5Ser), TOPMed rs2083929089, REVEL 0.13, AlphaMissense 0.06, Likely benign
- P5T (p.Pro5Thr), NCI-TCGA Cosmic COSV1000, cosmic curated COSV10003, Variant assessed as somatic; moderate impact.
- P7S (p.Pro7Ser), TOPMed rs1422074791, gnomAD rs1422074791, REVEL 0.36, MetaLR 0.28, Uncertain significance, SLC25A20-related disorder
- I8L (p.Ile8Leu), TOPMed rs1241000862, gnomAD rs1241000862
- I8M (p.Ile8Met), NCI-TCGA TCGA novel, MetaLR 0.38, MetaSVM -0.50, Variant assessed as somatic; moderate impact.
- I8T (p.Ile8Thr), gnomAD rs1175488561, REVEL 0.55, MetaLR 0.41
- I8V (p.Ile8Val), TOPMed rs1241000862, gnomAD rs1241000862, REVEL 0.30, MetaLR 0.38
- S9N (p.Ser9Asn), gnomAD rs1433882242
- S9T (p.Ser9Thr), gnomAD rs1433882242, MetaLR 0.53, MetaSVM -0.02
- P10L (p.Pro10Leu), rs376837831, ClinGen CA2387532, ClinVar RCV001958201, ClinVar RCV005278997, REVEL 0.43, MetaLR 0.50, Uncertain significance, Carnitine acylcarnitine translocase deficiency; Inborn genetic diseases
- P10Q (p.Pro10Gln), ESP rs376837831, ExAC rs376837831, TOPMed rs376837831, gnomAD rs376837831, REVEL 0.57, MetaLR 0.59, Uncertain significance
- P10S (p.Pro10Ser), rs753219087, ClinGen CA2387533, ClinVar RCV001146939, ExAC rs753219087, REVEL 0.46, MetaLR 0.39, Uncertain significance, Carnitine acylcarnitine translocase deficiency
- L11H (p.Leu11His), TOPMed rs1264464966
- N13S (p.Asn13Ser), Ensembl rs2083928693, MetaLR 0.21, MetaSVM -0.89
- L14V (p.Leu14Val), ExAC rs759378078, TOPMed rs759378078, gnomAD rs759378078, REVEL 0.16, MetaLR 0.31
- L15M (p.Leu15Met), ExAC rs763244156, gnomAD rs763244156, REVEL 0.47, MetaLR 0.55
- A16T (p.Ala16Thr), gnomAD rs1232415849
- A16V (p.Ala16Val), rs2083928547, ClinGen CA352639318, ClinVar RCV001144985, ClinVar RCV003331051, REVEL 0.89, MetaLR 0.75, Uncertain significance, Carnitine acylcarnitine translocase deficiency; not specified
- G17A (p.Gly17Ala), 1000Genomes rs550225133, ExAC rs550225133, gnomAD rs550225133, REVEL 0.87, MetaLR 0.87
- G17R (p.Gly17Arg), TOPMed rs2083928522, Conflicting interpretations, not specified; Carnitine acylcarnitine translocase deficiency
- F19L (p.Phe19Leu), gnomAD rs1291549848, MetaLR 0.35, MetaSVM -0.54
- G20D (p.Gly20Asp), ExAC rs748569316, gnomAD rs748569316, REVEL 0.97, MetaLR 0.79
- G20S (p.Gly20Ser), gnomAD rs1339380677, REVEL 0.65, MetaLR 0.52
- G21S (p.Gly21Ser), rs796052042, ClinGen CA312987, ClinVar RCV000186167, Ensembl rs796052042, AlphaMissense 0.94, MetaLR 0.79, Uncertain significance, not provided
- V22L (p.Val22Leu), Ensembl rs1559674116, REVEL 0.17, MetaLR 0.29
- C23* (p.Cys23Ter), NCI-TCGA Cosmic COSV5980, cosmic curated COSV59802, Variant assessed as somatic; high impact.
- L24V (p.Leu24Val), rs2106672482, ClinGen CA352639172, ClinVar RCV001892597, Ensembl rs2106672482, REVEL 0.18, MetaLR 0.26, Uncertain significance, Carnitine acylcarnitine translocase deficiency
- V25L (p.Val25Leu), cosmic curated COSV59802, ExAC rs777241185, TOPMed rs777241185, gnomAD rs777241185, REVEL 0.47, MetaLR 0.49, Uncertain significance
- V25M (p.Val25Met), rs777241185, ClinGen CA352639149, ClinVar RCV002631594, ExAC rs777241185, REVEL 0.73, MetaLR 0.69, Uncertain significance, Carnitine acylcarnitine translocase deficiency
- F26L (p.Phe26Leu), Ensembl rs575159358, REVEL 0.31, MetaLR 0.09
- F26V (p.Phe26Val), gnomAD rs1439890633, REVEL 0.38, MetaLR 0.18
- G28C (p.Gly28Cys), rs747335514, ClinGen CA2387519, ClinVar RCV001762807, ClinVar RCV002539863, REVEL 0.87, MetaLR 0.64, Conflicting interpretations, Carnitine acylcarnitine translocase deficiency
- G28D (p.Gly28Asp), rs2106672462, ClinGen CA352639079, ClinVar RCV001901126, Ensembl rs2106672462, AlphaMissense 1.00, MetaLR 0.73, Uncertain significance, Carnitine acylcarnitine translocase deficiency
- G28S (p.Gly28Ser), ExAC rs747335514, TOPMed rs747335514, gnomAD rs747335514, REVEL 0.71, MetaLR 0.61, Uncertain significance
- H29Y (p.His29Tyr), Ensembl rs1330949538, REVEL 0.74, MetaLR 0.48
- P30A (p.Pro30Ala), rs780569251, ClinGen CA2387517, cosmic curated COSV59804, ClinVar RCV000701401, REVEL 0.97, MetaLR 0.97, Uncertain significance, Carnitine acylcarnitine translocase deficiency; See cases
- P30S (p.Pro30Ser), rs780569251, ClinGen CA352639036, ClinVar RCV001058430, ExAC rs780569251, REVEL 0.97, MetaLR 0.96, Uncertain significance, Carnitine acylcarnitine translocase deficiency
- L31V (p.Leu31Val), NCI-TCGA Cosmic COSV1000, cosmic curated COSV10003, REVEL 0.72, MetaLR 0.69, Variant assessed as somatic; moderate impact.
- T33M (p.Thr33Met), ExAC rs756910774, gnomAD rs756910774, REVEL 0.80, MetaLR 0.65
- T33R (p.Thr33Arg), ExAC rs756910774, gnomAD rs756910774, REVEL 0.86, MetaLR 0.60
- V36=, NCI-TCGA TCGA novel, Variant assessed as somatic; low impact.
- R37* (p.Arg37Ter), rs776288377, ClinGen CA2387492, ClinVar RCV003875170, ExAC rs776288377, CADD 36.00, SIFT 0.01, Pathogenic
- R37G (p.Arg37Gly), ExAC rs776288377, TOPMed rs776288377, gnomAD rs776288377, REVEL 0.90, MetaLR 0.82, Pathogenic
- R37P (p.Arg37Pro), ESP rs371250509, ExAC rs371250509, TOPMed rs371250509, gnomAD rs371250509, REVEL 0.94, MetaLR 0.86, Uncertain significance, not specified
- R37Q (p.Arg37Gln), rs371250509, NCI-TCGA Cosmic COSV5980, cosmic curated COSV59804, ESP rs371250509, REVEL 0.89, MetaLR 0.73, Uncertain significance
- Q39P (p.Gln39Pro), NCI-TCGA Cosmic COSV5980, cosmic curated COSV59803, Variant assessed as somatic; moderate impact.
- Q39R (p.Gln39Arg), TOPMed rs2083881929, REVEL 0.96, MetaLR 0.87
- T40K (p.Thr40Lys), gnomAD rs1330560403, REVEL 0.90, MetaLR 0.67
- Q41* (p.Gln41Ter), rs1575992941, ClinGen CA352637664, ClinVar RCV003472838, Ensembl rs1575992941, CADD 37.00, SIFT 0.33, Pathogenic
- Q41R (p.Gln41Arg), gnomAD rs1441860684, REVEL 0.70, MetaLR 0.61
- P42S (p.Pro42Ser), ESP rs367835261, ExAC rs367835261, TOPMed rs367835261, gnomAD rs367835261, REVEL 0.52, MetaLR 0.47, Uncertain significance, Carnitine acylcarnitine translocase deficiency; Inborn genetic diseases
- P43L (p.Pro43Leu), cosmic curated COSV59802, ExAC rs758258325, gnomAD rs758258325, REVEL 0.17, MetaLR 0.18
- P43S (p.Pro43Ser), TOPMed rs1406980035, gnomAD rs1406980035, REVEL 0.10, MetaLR 0.14
- S44N (p.Ser44Asn), rs2083881740, ClinGen CA352637616, ClinVar RCV003058275, Ensembl rs2083881740, REVEL 0.11, MetaLR 0.29, Uncertain significance, Carnitine acylcarnitine translocase deficiency
- L45F (p.Leu45Phe), cosmic curated COSV59803, ExAC rs765457056, gnomAD rs765457056, REVEL 0.14, MetaLR 0.35
- L45S (p.Leu45Ser), gnomAD rs1178475298, REVEL 0.11, MetaLR 0.18
- G47E (p.Gly47Glu), cosmic curated COSV10610, ExAC rs761944287, gnomAD rs761944287, REVEL 0.61, MetaLR 0.63
- G47R (p.Gly47Arg), Ensembl rs769080522, SIFT 0.00
- Q48R (p.Gln48Arg), gnomAD rs1160197401, REVEL 0.20, MetaLR 0.29
- P50L (p.Pro50Leu), Ensembl rs866082015, MetaLR 0.28, MetaSVM -0.72
- P50S (p.Pro50Ser), cosmic curated COSV10739, TOPMed rs1323532383, REVEL 0.19, MetaLR 0.32
- M51V (p.Met51Val), gnomAD rs999921622, REVEL 0.23, MetaLR 0.22
- Y52H (p.Tyr52His), NCI-TCGA Cosmic COSV5980, cosmic curated COSV59802, Variant assessed as somatic; moderate impact.
- S53P (p.Ser53Pro), NCI-TCGA Cosmic COSV5980, cosmic curated COSV59803, Variant assessed as somatic; moderate impact.
- G54W (p.Gly54Trp), rs1035610382, ClinGen CA73998478, ClinVar RCV001806959, TOPMed rs1035610382, REVEL 0.90, MetaLR 0.83, Uncertain significance, not provided
- T55A (p.Thr55Ala), rs1002978497, ClinGen CA73998473, ClinVar RCV001806960, TOPMed rs1002978497, REVEL 0.33, MetaLR 0.20, Uncertain significance, not provided
- F56S (p.Phe56Ser), rs1216285427, ClinGen CA352637472, ClinVar RCV001209702, gnomAD rs1216285427, REVEL 0.70, MetaLR 0.49, Uncertain significance, Carnitine acylcarnitine translocase deficiency
- R60Q (p.Arg60Gln), rs761233598, ClinGen CA2387483, ClinVar RCV001144984, ClinVar RCV002557104, REVEL 0.48, MetaLR 0.53, Uncertain significance, Carnitine acylcarnitine translocase deficiency; Inborn genetic diseases
- R60W (p.Arg60Trp), rs764319600, ClinGen CA2387484, ClinVar RCV003332702, ExAC rs764319600, REVEL 0.70, MetaLR 0.68, Uncertain significance, not provided
- K61N (p.Lys61Asn), NCI-TCGA TCGA novel, MetaLR 0.39, MetaSVM -0.39, Variant assessed as somatic; moderate impact.
- T62A (p.Thr62Ala), Ensembl rs2106665823, REVEL 0.73, MetaLR 0.66
- L63P (p.Leu63Pro), NCI-TCGA Cosmic COSV1000, cosmic curated COSV10003, Variant assessed as somatic; moderate impact.
- L63V (p.Leu63Val), rs1044481006, ClinGen CA73998456, ClinVar RCV001963565, TOPMed rs1044481006, REVEL 0.18, MetaLR 0.19, Uncertain significance, Carnitine acylcarnitine translocase deficiency
- F64* (p.Phe64Ter), NCI-TCGA TCGA novel, CADD 26.00, Variant assessed as somatic; high impact.
- F64L (p.Phe64Leu), Ensembl rs1559672385, REVEL 0.25, MetaLR 0.16
- F64S (p.Phe64Ser), Ensembl rs1559672383, MetaLR 0.30, MetaSVM -0.78
- R65G (p.Arg65Gly), gnomAD rs1199221551
- E66D (p.Glu66Asp), TOPMed rs1275508003, gnomAD rs1275508003, REVEL 0.60, MetaLR 0.57
- E66K (p.Glu66Lys), NCI-TCGA Cosmic COSV5980, cosmic curated COSV59803, Variant assessed as somatic; moderate impact.
- I68T (p.Ile68Thr), ESP rs144334697, ExAC rs144334697, TOPMed rs144334697, gnomAD rs144334697, REVEL 0.59, MetaLR 0.51
- T69M (p.Thr69Met), rs138433512, ClinGen CA2387458, ClinVar RCV002282823, ClinVar RCV003101614, REVEL 0.16, MetaLR 0.22, Uncertain significance, Inborn genetic diseases; not specified; Carnitine acylcarnitine translocase defi
- T69P (p.Thr69Pro), Ensembl rs2106658682
- G70E (p.Gly70Glu), ExAC rs776327302, TOPMed rs776327302, gnomAD rs776327302, REVEL 0.91, MetaLR 0.81
- G70R (p.Gly70Arg), Ensembl rs959672303
- G70V (p.Gly70Val), ExAC rs776327302, TOPMed rs776327302, gnomAD rs776327302, REVEL 0.89, MetaLR 0.75
- R73Q (p.Arg73Gln), TOPMed rs1476582775, gnomAD rs1476582775, REVEL 0.57, MetaLR 0.53, Uncertain significance, Inborn genetic diseases
- R73W (p.Arg73Trp), rs376860154, 1000Genomes rs376860154, ESP rs376860154, ExAC rs376860154, REVEL 0.70, MetaLR 0.78, Uncertain significance, Inborn genetic diseases
- M75T (p.Met75Thr), rs2470603735, ClinGen CA352634739, ClinVar RCV003237215, Uncertain significance, not provided
- M75V (p.Met75Val), rs1244245866, ClinGen CA352634745, ClinVar RCV003272824, gnomAD rs1244245866, REVEL 0.70, MetaLR 0.32, Uncertain significance, Inborn genetic diseases
- A76D (p.Ala76Asp), gnomAD rs1456549303, REVEL 0.80, MetaLR 0.63
- A76P (p.Ala76Pro), rs150516570, ClinGen CA2387454, ClinVar RCV000807267, ClinVar RCV000998073, REVEL 0.67, MetaLR 0.52, Uncertain significance, not provided; Carnitine acylcarnitine translocase deficiency
- P78A (p.Pro78Ala), gnomAD rs1237638371, REVEL 0.69, MetaLR 0.59
- P78H (p.Pro78His), ExAC rs774897635, TOPMed rs774897635, gnomAD rs774897635, REVEL 0.90, MetaLR 0.70
- P78L (p.Pro78Leu), ExAC rs774897635, TOPMed rs774897635, gnomAD rs774897635, REVEL 0.91, MetaLR 0.66, Uncertain significance, Inborn genetic diseases
- I79M (p.Ile79Met), TOPMed rs1351781504
- I79T (p.Ile79Thr), NCI-TCGA TCGA novel, MetaLR 0.59, MetaSVM 0.27, Variant assessed as somatic; moderate impact.
- I79V (p.Ile79Val), rs771999740, NCI-TCGA Cosmic COSV1000, ExAC rs771999740, TOPMed rs771999740, REVEL 0.27, MetaLR 0.26, Variant assessed as somatic; moderate impact.
- I80T (p.Ile80Thr), TOPMed rs1425564816, gnomAD rs1425564816, REVEL 0.38, MetaLR 0.32
- G81E (p.Gly81Glu), Ensembl rs868158647
- G81R (p.Gly81Arg), rs778739484, ClinGen CA2387450, ClinVar RCV003388421, ExAC rs778739484, REVEL 0.81, MetaLR 0.56, Likely pathogenic, Carnitine acylcarnitine translocase deficiency
- V82G (p.Val82Gly), TOPMed rs1402001280, gnomAD rs1402001280, REVEL 0.94, MetaLR 0.63
- T83S (p.Thr83Ser), NCI-TCGA TCGA novel, MetaLR 0.37, MetaSVM -0.52, Variant assessed as somatic; moderate impact.
- P84S (p.Pro84Ser), ExAC rs757186009, gnomAD rs757186009, REVEL 0.86, MetaLR 0.76
- M85I (p.Met85Ile), gnomAD rs1330009477, MetaLR 0.22, MetaSVM -0.82
- M85K (p.Met85Lys), rs1374102445, ClinGen CA352634543, ClinVar RCV003119031, ClinVar RCV006363389, REVEL 0.84, MetaLR 0.40, Uncertain significance, Inborn genetic diseases; Carnitine acylcarnitine translocase deficiency
- M85T (p.Met85Thr), TOPMed rs1374102445, gnomAD rs1374102445, REVEL 0.76, MetaLR 0.37, Uncertain significance
- M85V (p.Met85Val), gnomAD rs1454498043, REVEL 0.48, MetaLR 0.20
- A87T (p.Ala87Thr), Ensembl rs995000320
- A87V (p.Ala87Val), rs749507449, ClinGen CA2387448, NCI-TCGA Cosmic COSV5980, ClinVar RCV002651704, REVEL 0.90, MetaLR 0.76, Uncertain significance, not provided; Carnitine acylcarnitine translocase deficiency
- V88A (p.Val88Ala), TOPMed rs1361378026, gnomAD rs1361378026, REVEL 0.78, MetaLR 0.42
- V88M (p.Val88Met), rs145573028, ClinGen CA2387447, ClinVar RCV001365460, ESP rs145573028, REVEL 0.65, MetaLR 0.44, Uncertain significance, Carnitine acylcarnitine translocase deficiency
- F90C (p.Phe90Cys), gnomAD rs1405179913, REVEL 0.93, MetaLR 0.86
- G92R (p.Gly92Arg), TOPMed rs1222742008, gnomAD rs1222742008, REVEL 0.85, MetaLR 0.71
- F93L (p.Phe93Leu), Ensembl rs764937492, REVEL 0.64, MetaLR 0.34
- G94A (p.Gly94Ala), gnomAD rs2083813222, REVEL 0.60, MetaLR 0.31
- L95F (p.Leu95Phe), TOPMed rs2083813177
- G96R (p.Gly96Arg), TOPMed rs1284938291, gnomAD rs1284938291, REVEL 0.78, MetaLR 0.67
- K97N (p.Lys97Asn), NCI-TCGA Cosmic COSV5980, Variant assessed as somatic; moderate impact.
- K97R (p.Lys97Arg), NCI-TCGA TCGA novel, MetaLR 0.66, MetaSVM 0.27, Variant assessed as somatic; high impact.
- K98* (p.Lys98Ter), rs1553686321, ClinGen CA352634302, ClinVar RCV000532365, Ensembl rs1553686321, Pathogenic
- K98N (p.Lys98Asn), gnomAD rs1438314972, REVEL 0.19, MetaLR 0.32
- Q101* (p.Gln101Ter), rs752042051, ClinGen CA2387442, ClinVar RCV003625061, ExAC rs752042051, CADD 37.00, Pathogenic
- Q101E (p.Gln101Glu), ExAC rs752042051, gnomAD rs752042051, Pathogenic
- Q101K (p.Gln101Lys), ExAC rs752042051, gnomAD rs752042051, Pathogenic
- H103Y (p.His103Tyr), TOPMed rs2083813014, gnomAD rs2083813014, REVEL 0.28, MetaLR 0.17
- E105K (p.Glu105Lys), Ensembl rs113317403
- L108F (p.Leu108Phe), TOPMed rs890427954, gnomAD rs890427954, REVEL 0.59, MetaLR 0.56
- S109R (p.Ser109Arg), gnomAD 3-48879448-G-T, REVEL 0.26, MetaLR 0.33
- Y110C (p.Tyr110Cys), TOPMed rs2083784197, REVEL 0.86, MetaLR 0.61
- P111P (p.Pro111Pro), rs758938664, gnomAD 3-48879442-G-T, CADD 3.68, SIFT 0.12
- P111L (p.Pro111Leu), gnomAD 3-48879443-G-A, REVEL 0.33, MetaLR 0.19
- P111S (p.Pro111Ser), gnomAD 3-48879444-G-A, REVEL 0.19, MetaLR 0.26
- Q112H (p.Gln112His), rs765641042, ClinGen CA2387416, ClinVar RCV002799134, ExAC rs765641042, REVEL 0.53, MetaLR 0.49, Uncertain significance, Inborn genetic diseases
- Q112P (p.Gln112Pro), ExAC rs201608596, TOPMed rs201608596, gnomAD rs201608596, REVEL 0.75, MetaLR 0.58
- Q112R (p.Gln112Arg), ExAC rs201608596, TOPMed rs201608596, gnomAD rs201608596, REVEL 0.69, MetaLR 0.43
- L113P (p.Leu113Pro), gnomAD 3-48879437-A-G, REVEL 0.65, MetaLR 0.60
- L113R (p.Leu113Arg), gnomAD 3-48879437-A-C, REVEL 0.61, MetaLR 0.51
- F114L (p.Phe114Leu), gnomAD 3-48879432-CA-C, CADD 29.50
- F114F (p.Phe114Phe), rs1005857338, gnomAD 3-48879433-A-G, CADD 11.20, SIFT 0.00
- A115V (p.Ala115Val), TOPMed rs891099813, MetaLR 0.19, MetaSVM -0.87
- A116L (p.Ala116Leu), gnomAD 3-48879428-GC-G, CADD 32.00
- M118I (p.Met118Ile), TOPMed rs1371755364, gnomAD rs1371755364, REVEL 0.68, MetaLR 0.44, Uncertain significance, Inborn genetic diseases
- M118L (p.Met118Leu), 1000Genomes rs564673038, ExAC rs564673038, gnomAD rs564673038, REVEL 0.47, MetaLR 0.30
- M118T (p.Met118Thr), TOPMed rs1051193858
- S120C (p.Ser120Cys), NCI-TCGA Cosmic COSV1000, REVEL 0.86, MetaLR 0.69, Variant assessed as somatic; moderate impact.
- S120P (p.Ser120Pro), rs149174359, ClinGen CA2387414, ClinVar RCV000293988, ClinVar RCV000507911, REVEL 0.93, MetaLR 0.78, Conflicting interpretations, Inborn genetic diseases; Carnitine acylcarnitine translocase deficiency; not spe
- S120S (p.Ser120Ser), rs767041501, gnomAD 3-48879415-A-C, CADD 7.64, SIFT 0.08
- G121G (p.Gly121Gly), rs566702908, gnomAD 3-48879412-G-T, CADD 0.43, SIFT 0.04
- V122I (p.Val122Ile), rs150419695, ClinGen CA2387410, ClinVar RCV001068611, ClinVar RCV002554550, REVEL 0.19, MetaLR 0.19, Uncertain significance, Inborn genetic diseases; Carnitine acylcarnitine translocase deficiency
- V122L (p.Val122Leu), rs150419695, ClinGen CA2387411, ClinVar RCV001201938, ClinVar RCV004033518, REVEL 0.42, MetaLR 0.26, Uncertain significance, Inborn genetic diseases; Carnitine acylcarnitine translocase deficiency
- V122V (p.Val122Val), rs1455799240, gnomAD 3-48879409-T-C, CADD 3.50, SIFT 0.08
- F123S (p.Phe123Ser), gnomAD 3-48879407-A-G, REVEL 0.64, MetaLR 0.29
- T124I (p.Thr124Ile), gnomAD 3-48879404-G-A, REVEL 0.81, MetaLR 0.66
- T125S (p.Thr125Ser), TOPMed rs777628898, gnomAD rs777628898, REVEL 0.57, MetaLR 0.39
- T125A (p.Thr125Ala), gnomAD 3-48879402-T-C, REVEL 0.57, MetaLR 0.30
- G126* (p.Gly126Ter), NCI-TCGA Cosmic COSV1000, NCI-TCGA Cosmic COSV5980, Variant assessed as somatic; high impact.
- G126E (p.Gly126Glu), gnomAD 3-48879398-C-T, REVEL 0.39, MetaLR 0.37
- I127I (p.Ile127Ile), rs763005130, gnomAD 3-48879394-G-A, CADD 8.89, SIFT 0.15
- I127V (p.Ile127Val), gnomAD 3-48879396-T-C, REVEL 0.39, MetaLR 0.25
- M128I (p.Met128Ile), Ensembl rs2083783752, REVEL 0.70, MetaLR 0.44
- M128T (p.Met128Thr), ExAC rs773117326, gnomAD rs773117326, REVEL 0.59, MetaLR 0.20
- M128V (p.Met128Val), gnomAD rs1480899393, REVEL 0.61, MetaLR 0.26, Uncertain significance, Carnitine acylcarnitine translocase deficiency
- T129N (p.Thr129Asn), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- T129S (p.Thr129Ser), Ensembl rs2083783731, MetaLR 0.36, MetaSVM -0.55
- P130S (p.Pro130Ser), TOPMed rs1191735542, gnomAD rs1191735542, REVEL 0.98, MetaLR 0.97
- E132* (p.Glu132Ter), rs769748915, ClinGen CA73992035, ClinVar RCV003624597, ExAC rs769748915, AlphaMissense 0.99, MetaLR 0.83, Pathogenic
- E132K (p.Glu132Lys), ExAC rs769748915, TOPMed rs769748915, gnomAD rs769748915, REVEL 0.91, AlphaMissense 0.99, Pathogenic
- R133G (p.Arg133Gly), ExAC rs748394731, TOPMed rs748394731, gnomAD rs748394731, REVEL 0.77, MetaLR 0.74, Pathogenic, in CACTD
- R133Q (p.Arg133Gln), ExAC rs773887820, TOPMed rs773887820, gnomAD rs773887820, REVEL 0.74, MetaLR 0.70
- R133W (p.Arg133Trp), rs748394731, ClinGen CA2387406, ClinVar RCV001199860, ClinVar RCV003945915, REVEL 0.83, MetaLR 0.76, Pathogenic/Likely pathogenic, Carnitine acylcarnitine translocase deficiency
- R133R (p.Arg133Arg), rs768931116, gnomAD 3-48879376-C-A, CADD 11.80, SIFT 0.00
- I134N (p.Ile134Asn), NCI-TCGA Cosmic COSV1000, Variant assessed as somatic; moderate impact.
Public SLC25A20 analysis runs
- SLC25A20 analysis run — SLC25A20 (529 variants) — completed 2026-08-20